A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions

NCT02201316 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastritis

Interventions

DRUG: Reference mosapride citrate (GASMOTIN)
DRUG: GR107719B (Formulation 1)
DRUG: GR107719B (Formulation 2)

Sponsor

GlaxoSmithKline